Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Gurbuxani S, Anastasi J, Hyjek E (2009) Diffuse large B-cell lymphoma–more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch Pathol Lab Med 133:1121–1134PubMed
2.
Gascoyne RD, Campo E, Jaffe ES, Chan WC et al (2017) Diffuse large B cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues, revised 4 edn. International Agency for Research on Cancer (IARC), Lyon, pp P292–P293
3.
Diebold J, Anderson JR, Armitage JO, Connors JM, Maclennan KA, Müller-Hermelink HK et al (2002) Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 43(1):97–104CrossRefPubMed
4.
Sakakibara A, Kohno K, Kuroda N, Yorita K, Megahed NA, Eladl AE et al (2018) Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: two cases highlighting a broad diversity in the diagnostics. Pathol Int 68(4):251–255CrossRefPubMed
5.
Romero-Guadarrama MB, Aguilar-Ayala LE, Ott G, Pérez-Espinosa J (2012) Diffuse large B-cell lymphoma with anaplastic clear cells: a rare variant. Open J Pathol 2:150–154CrossRef
6.
Tilly H, Gaulard P, Lepage E et al (1997) Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 90:3727–3734PubMed
7.
Lai R, Medeiros LJ, Dabbagh L, Formenti KS, Coupland RW (2000) Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 13:223–228CrossRefPubMed
8.
Li M, Liu Y, Wang Y et al (2017) Anaplastic variant of diffuse large Bcell lymphoma displays intricate genetic alterations and distinct biological features. Am J Surg Pathol 41:1322–1332CrossRefPubMed
9.
Nakamura S, Shiota M, Nakagawa A et al (1997) Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420–1432CrossRefPubMed
10.
Sarkozy C, Molina T, Ghesquieres H et al (2017) Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 102:150–159CrossRefPubMedPubMedCentral
11.
Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon
12.
Evens AM, Kanakry JA, Sehn LH et al (2015) Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 90:778–783CrossRefPubMed
13.
Mittal M, Puri A, Nangia R, Sachdeva A (2015) Follicular lymphoma transforming into anaplastic diffuse large B-cell lymphoma of oral cavity: a case report with review of literature. J Oral Maxillofac Pathol 19(3):379–384CrossRefPubMedPubMedCentral
14.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A et al (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715–2724CrossRefPubMedPubMedCentral
15.
Slack GW, Steidl C, Sehn LH, Gascoyne RD (2014) CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol 167(5):608–617CrossRefPubMed
16.
Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L et al (2015) The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS ONE 10(5):e0126615CrossRefPubMedPubMedCentral
17.
Collie AMB, Hill BT, Manilich EA, Smith MR, His ED (2013) CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype. Blood 122:4318
Metadata
Title
Anaplastic Diffuse Large B Cell Lymphoma: A Single Center Experience
Authors
Neha Singh
Ridhi Sood
Narendra Agrawal
Sunil Pasricha
Anurag Mehta
Publication date
01-07-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01096-8

Other articles of this Issue 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Go to the issue

Original Article

Rapid and Reliable One-Step ABO Genotyping Using Direct Real-Time Allele-Specific PCR and Melting Curve Analysis Without DNA Preparation

Correspondence

Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma

Correspondence

Mechanical Cryopreservation of Peripheral Blood Stem Cell: Initial Experience from a Tertiary Care Hospital

Original Article

Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria

Short Communication

Obituary: Professor Sir David John Weatherall GBE, MD, FRCP, FRS

Correspondence

Spontaneous Acute Subdural Hematoma as an Initial Presentation of Chronic Myeloid Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits